Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon α1B for Bronchiolitis in Children: a Systematic Review and Meta-Analysis
Table 2
GRADE evidence profile.
Certainty assessment
No of patients
Effect
Certainty
Outcome
Study design
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerations
2ug/kg IFNα1b
4ug/kg IFNα1b
Relative (95% CI)
Absolute (95% CI)
①
RCT
Very serious a
Not serious
Not serious
Not serious
None
366
367
—
MD 0.40 lower (0.73 lower to 0.07 lower)
⊕⊕○○ LOW
②
RCT
Very serious a
Not serious
Not serious
Not serious
None
240
247
—
MD 0.60 lower (1.05 lower to 0.14 lower)
⊕⊕○○ LOW
③
RCT
Very serious a
Serious b
Not serious
Not serious
None
392
405
—
MD 0.13 lower (0.43 lower to 0.16 higher)
⊕○○○ VERY LOW
④
RCT
Very serious a
Serious b
Not serious
Not serious
None
140
163
—
MD 0.25 lower (0.94 lower to 0.43 higher)
⊕○○○ VERY LOW
⑤
RCT
Very serious a
Not serious
Not serious
Not serious
None
187
194
—
MD 0.62 lower (1.17 lower to 0.06 lower)
⊕⊕○○ LOW
⑥
RCT
Very serious a
Not serious
Not serious
Not serious
None
88
91
—
MD 0.01 higher (0.37 lower to 0.39 higher)
⊕⊕○○ LOW
⑦
RCT
Very serious a
Not serious
Not serious
Not serious
None
18/610 (3.0%)
17/641 (2.7%)
RR 1.07 (0.58 TO 1 .98)
2 more per 1,000 (from 11 fewer to 26 more)
⊕⊕○○ LOW
CI: confidence interval; SMD: standardized mean difference; RR: risk ratio; RD: risk difference. a. Using a wrong method for randomization or did not perform allocation conceal; b. Included RCTs were distributed on both side of the invalidity line. ① The duration of hospital stays; ② three depressions sign disappearing time; ③ cough disappearance time; ④ pulmonary rales disappearing time; ⑤ wheeze disappearing time; ⑥ wheezing sound disappearing time; ⑦ adverse event rates.
